Abstract
Background/Objective: The management of patients with atopic dermatitis (AD) is often difficult for both patients and physicians. We hypothesized that repeated intramuscular injections of autologous immunoglobulin can induce clinical improvement in patients with AD by correcting immune dysfunction. Methods: Seventeen adult patients with severe AD were treated by intramuscular injection of 50 mg autologous immunoglobulin (mainly IgG with a purity ≥97%) twice a week for 4 weeks. The standardized clinical severity scoring system for AD (SCORAD) value and serum IgE concentration were measured at baseline and at 4, 8, and 12 weeks. Results: SCORAD values and serum IgE concentrations significantly decreased at 4, 8, and 12 weeks compared to baseline (p < 0.05). No significant side effects were observed. Conclusions: Repeated intramuscular injections of autologous immunoglobulin significantly decreased the clinical severity and serum IgE concentration in patients with severe AD. Further studies are required to evaluate the clinical significance of these findings.
Journal Section:
Editor's choice
References
1.
Akdis CA, Akdis M, Bieber T, et al; European Academy of Allergology and Clinical Immunology/American Academy of Allergy Asthma and Immunology: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169.
[PubMed]
2.
Bieber T: Atopic dermatitis. N Engl J Med 2008;358:1483-1494.
[PubMed]
3.
Krathen RA, Hsu S: Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-340.
[PubMed]
4.
Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suarez-Farinas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130-139.
[PubMed]
5.
Hua TC, Hwang CY, Chen YJ, Chu SY, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN: The natural course of early-onset atopic dermatitis in Taiwan: a population-based cohort study. Br J Dermatol 2014;170:130-135.
[PubMed]
6.
Takemori T, Rajewsky K: Mechanism of neonatally induced idiotype suppression and its relevance for the acquisition of self-tolerance. Immunol Rev 1984;79:103-117.
[PubMed]
7.
Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW: Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol 2011;29:2787-2794.
[PubMed]
8.
Nahm DH, Cho SM, Kim ME, Kim YJ, Jeon SY: Autologous immunoglobulin therapy in patients with severe recalcitrant atopic dermatitis: a preliminary report. Allergy Asthma Immunol Res 2014;6:89-94.
[PubMed]
9.
Hanifin JM, Rajka G: Diagnostic features of atopic eczema. Acta Derm Venereol 1980;92:44-47.
10.
European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993;186:23-31.
[PubMed]
11.
Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB: Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007;157:645-648.
[PubMed]
12.
Andrew SM, Titus JA: Purification of immunoglobulin G. Curr Protoc Immunol 2001, DOI: 10.1002/0471142735.im0207s21.
[PubMed]
13.
Buchacher A, Iberer G: Purification of intravenous immunoglobulin G from human plasma - aspects of yield and virus safety. Biotechnol J 2006;1:148-163.
[PubMed]
14.
Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
[PubMed]
15.
Subba Rao PV, McCartney-Francis NL, Metcalfe DD: An avidin-biotin microELISA for rapid measurement of total and allergen-specific human IgE. J Immunol Methods 1983;57:71-85.
[PubMed]
16.
Nahm DH, Kim HY, Park HS: House dust mite-specific IgE antibodies in induced sputum are associated with sputum eosinophilia in mite-sensitive asthmatics. Ann Allergy Asthma Immunol 2000;85:129-133.
[PubMed]
17.
Steffen C: Why a historical approach has clinical benefits: Staphylococcus toxoid and autohemotherapy. Skinmed 2005;4:316-319.
[PubMed]
18.
Asefi M, Augustin M: Regulative therapy: treatment with nonspecific stimulants in dermatology in traditional and modern perspectives. Forsch Komplementarmed 1999;6(suppl 2):9-13.
[PubMed]
19.
Schafer T: Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol 2004;93(suppl 1):5-10.
[PubMed]
20.
Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E: Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 2003;148:307-313.
[PubMed]
21.
Staubach P, Onnen K, Vonend A, Metz M, Siebenhaar F, Tschentscher I, Opper B, Magerl M, Ludtke R, Kromminga A, Maurer M: Autologous whole blood injections to patients with chronic urticaria and a positive autologous serum skin test: a placebo-controlled trial. Dermatology 2006;212:150-159.
[PubMed]
22.
Debbarman P, Sil A, Datta PK, Bandyopadhyay D, Das NK: Autologous serum therapy in chronic urticaria: a promising complement to antihistamines. Indian J Dermatol 2014;59:375-382.
[PubMed]
23.
Cho SM, Kim ME, Kim JY, Park JC, Nahm DH: Clinical efficacy of autologous plasma therapy for atopic dermatitis. Dermatology 2014;228:71-77.
[PubMed]
24.
Quinti I, Coluzzi S, Pulvirenti F, Prezzo A, Girelli G: Polyvalent immunoglobulins: challenges and perspectives. Blood Transfus 2013;11(suppl 4):40-44.
[PubMed]
25.
Turner PJ, Kakakios A, Wong LC, Wong M, Campbell DE: Intravenous immunoglobulin to treat severe atopic dermatitis in children: a case series. Pediatr Dermatol 2012;29:177-181.
[PubMed]
26.
Lamb SR, Rademaker M: Intravenous immunoglobulin therapy for the treatment of severe atopic dermatitis. Expert Opin Pharmacother 2001;2:67-74.
[PubMed]
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
